Study Examines Patient Perceptions of Marijuana as Glaucoma Treatment
Research shows patients with glaucoma are likely to encounter conflicting opinions on marijuana’s role in glaucoma therapy, especially from dispensaries.
Miscellaneous Ocular Agents
Evaluating Reluctance to Embrace Selective Laser Trabeculoplasty as Front-Line Therapy
A growing body of research shows SLT for first-line glaucoma therapy works as well as drops — so why aren’t clinician’s embracing it?
TECNIS Eyhance Intraocular Lens Approved for Cataract Patients
The new approvals are the latest in Johnson & Johnson’s IOLs; the Company claims the new TECNIS Eyhance IOL can slightly extend the depth of focus and deliver better image contrast.
NDA Submitted for MydCombi, a Novel Mydriatic Agent
The NDA submission is supported by data from the phase 3 MIST-1 and MIST-2 studies.
Tepezza Supply Shortage Expected Soon
As both the vaccine and Tepezza are being manufactured at Catalent, the government has prioritized the manufacturing of the vaccine thereby resulting in cancellation of previously contracted Tepezza orders.
Cystadrops Now Available for Patients With Cystinosis
The Food and Drug Administration approved Cystadrops in August 2020.
Levodopa Benefits Neovascular Age-Related Macular Degeneration
Levodopa is safe and well-tolerated, improves visual outcomes, and delays anti-VEGF treatment.
Cystadrops Approved to Treat Corneal Crystal Deposits in Cystinosis
Cystinosis is a rare, multisystem genetic disorder caused by an accumulation of cystine crystals throughout the body, including the eyes.
FDA Warns of Risks Associated With Intraocular Use of Moxifloxacin
According to the Agency, 29 reports of TASS were identified following a search of the FDA Adverse Event Reporting System database through December 19, 2019.
Upneeq Approved for Acquired Blepharoptosis
The FDA has approved Upneeq™ (oxymetazoline hydrochloride ophthalmic solution; Osmotica) for the treatment of acquired blepharoptosis in adults.
